Accretion Nutraveda IPO offers a high‑growth, early‑stage Ayurvedic and nutraceutical manufacturing play with very strong return ratios, improving scale and typical SME‑segment risks plus a high minimum application size.
Accretion Nutraveda IPO overview
-
Accretion Nutraveda Ltd, incorporated in 2021, manufactures Ayurvedic and nutraceutical products in multiple dosage forms—tablets, capsules, oral liquids, powders, oils, balms, creams and gels.
- The company blends Ayurveda with modern science to address liver care, women’s health, bone and joint health, cognitive support and respiratory wellness.
- It serves customers in India and exports to Sri Lanka, Singapore and the USA, operating from a 10,763 sq. ft. manufacturing facility in Gujarat with modern infrastructure and QC systems.
Key IPO details, dates and lot size
-
IPO schedule:
- Open date: 28 January 2026.
- Close date: 30 January 2026.
- Basis of allotment: 2 February 2026.
- Refunds and Demat credit: 3 February 2026.
- Listing date: 4 February 2026 (cut‑off 5 PM on closing day).
- IPO Details:
- Face Value :- Rs 10 per share
- Price band :- Rs 122 to Rs 129
- Sale Type :- Fresh Capital
- Total issue size :-Rs 25 Cr
- Market lot and minimum investment:
- Minimum market lot: 2,000 shares.
- Retail minimum / maximum: 2,000 shares with application amount ₹2,58,000, putting it in the high‑ticket SME IPO bracket.
- Investor reservation:
- Anchor: 5,46,000 shares (28.44%).
- QIB (ex‑anchor): 3,62,000 shares (18.85%).
- NII: 2,76,000 shares (14.37%).
- Retail: 6,40,000 shares (33.33%).
- Anchor investors:
- Anchor bidding date: 27 January 2026.
- Anchor size: ₹7.04 crore via 5,46,000 shares.
- Lock‑in: 50% till 4 March 2026 (30 days), remaining 50% till 3 May 2026 (90 days).
- Promoters and shareholding:
- Promoters: Mayur Popatlal Sojitra, Ankurkumar Shantilal Patel, Paraskumar Vinubhai Parmar, Hardik Mukundbhai Prajapati, Harshad Nanubhai Rathod and Vivek Ashok Kumar Patel.
- Promoter holding pre‑issue: 53,20,000 shares (100%).
- Promoter holding post‑issue: 72,40,000 shares (73.48%), indicating strong ongoing control.
- Objective of the issue:
- Purchase of machineries for automation at existing unit – ₹4.22 crore.
- Purchase of machineries for new manufacturing setup – ₹8.03 crore.
- Funding working capital requirements – ₹5.50 crore.
- General corporate purposes – balance.
Financials and valuation snapshot
|
Period Ended |
30 Sep 2025 |
31 Mar 2025 |
31 Mar 2024 |
31 Mar 2023 |
|
16.35 |
10.86 |
4.64 |
4.06 |
|
|
14.07 |
16.06 |
5.20 |
3.07 |
|
|
2.33 |
2.61 |
0.82 |
0.28 |
|
|
3.29 |
3.65 |
1.21 |
0.59 |
|
|
8.26 |
5.35 |
1.08 |
0.26 |
|
|
2.95 |
4.86 |
0.72 |
-0.10 |
|
|
4.43 |
3.86 |
2.17 |
1.97 |
|
|
Amount in ₹ Crore |
||||
- FY2025 metrics:
- ROE: 81.22%.
- ROCE: 36.98%.
- EBITDA margin: 22.79%.
- PAT margin: 16.33%.
- Debt‑equity ratio: not specified in extract (implied low equity base magnifying ROE).
- EPS (basic): ₹7.19.
- RoNW: 48.85%.
- NAV per share: ₹14.72.
- P/E: N/A (price band not visible here).
- Peer comparison (Ayurvedic/nutraceutical SMEs):
- Walpar Nutritions: EPS ₹1.80; P/E 23.94; RoNW 11.27%; NAV ₹13.65; income ₹60.26 crore.
- Influx Healthtech: EPS ₹7.31; P/E 25.93; RoNW 36.72%; NAV ₹5.31; income ₹104.99 crore.
Strengths
- Focused presence in high‑growth Ayurvedic and nutraceutical space, combining traditional formulations with evidence‑based product positioning.
- Wide dosage range – tablets, capsules, liquids, powders, oils, balms, creams and gels – allows catering to varied patient and doctor preferences.
- Rapid scale‑up with revenue rising from ₹3.07 crore in FY2023 to ₹16.06 crore in FY2025, plus ₹14.07 crore in just six months to Sep 2025, signalling strong growth momentum.
- Robust profitability – FY2025 EBITDA margin at 22.79% and PAT margin at 16.33% indicate attractive economics for a young nutraceutical manufacturer.
- Exceptional return metrics with ROE of 81.22% and RoNW of 48.85% in FY2025, reflecting high earnings on a relatively small equity base.
- Diversified therapeutic coverage across liver care, women’s health, bone and joint health, cognitive support and respiratory health, reducing single‑indication risk.
- Exports to Sri Lanka, Singapore and the USA provide geographic diversification and potential for higher‑margin international business.
Risks
- SME‑type IPO with high minimum lot size (2,000 shares, ₹2,58,000) restricts participation to investors comfortable with larger tickets and higher risk.
- Very short operating history (incorporated 2021) and rapid revenue jump increase sustainability and execution risk.
- Extremely high ROE (81.22%) largely reflects a small equity base; ratios may normalise as capital base expands post‑IPO.
- Reliance on regulatory approvals and compliance in Ayurvedic and nutraceutical segments—any tightening of norms can affect product lines.
- Open A Free Demat Account TodayGet StartedDocuments To Be Kept Handy
- PAN Card
- Cancelled Cheque
- Latest 6 month Bank Statement (Only for Derivatives Trading)
